The Activated Clotting Time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration

Journal of Invasive Cardiology

Volumn 17, Issue 8, 2005, Pages 416-421

  Cavusoglu, Erdal ^a   Lakhani, Manish ^a   Marmur, Jonathan D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; DOSE RESPONSE; DRUG MONITORING; DRUG SAFETY; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; THROMBOCYTOPENIA; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; BLOOD; BLOOD CLOTTING; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; SAFETY; THROMBOSIS;

ANGINA PECTORIS; ANTICOAGULANTS; BLOOD COAGULATION; CORONARY ANGIOGRAPHY; DALTEPARIN; ENOXAPARIN; FEMALE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SAFETY; THROMBOSIS; WHOLE BLOOD COAGULATION TIME;

EID: 25144438688     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
2. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
3. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997;337:447-452.
4. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
5. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
6. Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003;41:394-402.
7. Montalescot G, Cohen M. Low molecular weight heparins in the cardiac catheterization laboratory. J Thromb Thrombolysis 1999;7:319-323.
8. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354:708-715.
9. Greiber S, Weber U, Galle J, et al. Activated clotting time is not a sensitive parameter to monitor anticoagulation with low molecular weight heparin in hemodialysis. Nephron 1997;76:15-19.
10. Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent - a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999;81:214-220.
11. Linkins LA, Julian JA, Rischke J, et al. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 2002;107:241-244.
12. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 2004;61:163-170.
13. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
14. Boneu B. Low molecular weight heparin therapy: Is monitoring needed? Thromb Haemost 1994;72:330-334.
15. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecularweight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus. Am Heart J 2002;144:615-624.
16. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
17. Harenberg J, Stehle G, Dempfle CE, et al. The pharmacological profile of the low molecular weight heparin 21-23 in man: Anticoagulant, lipolytic and protamine reversible effects. Folia Haematol Int Mag Klin Morphol Blutforsch 1989;116:967-680.
18. Kroneman H, Eikelboom BC, Knot EA, et al. Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting. J Vasc Surg 1991;14:208-214.
19. Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002;116:178-186.
20. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-1395.
21. Lawrence M, Mixon TA, Cross D, et al. Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention. Catheter Cardiovasc Interv 2004;61:52-55.
22. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-1082.
23. Henry TD, Satran D, Knox LL, et al. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Am Heart J 2001;142:590-593.
24. Moliterno DJ, Hermiller JB, Kereiakes DJ, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol 2003;42:1132-1139.
25. Saw J, Kereiakes DJ, Mahaffey KW, et al. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thromb Res 2003;112:301-306.
26. Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: Correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 1993;23(Suppl 1):89-98.
27. Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999;104:230-240.
28. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: Aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961-966.
29. Narins CR, Hillegass WB, Jr., Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-671.
30. Brener SJ, Moliterno DJ, Lincoff AM, et al. Relationship between activated clotting time and ischemic or hemorrhagic complications: Analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004;110:994-998.
31. Kitchen S, Iampietro R, Woolley AM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: Inter-assay variability. Thromb Haemost 1999;82:1289-1293.
32. Depasse F, Gilbert M, Goret V, Rolland N, Samama MM. Anti-Xa monitoring: inter-assay variability. Thromb Haemost 2000;84:1122-1123.
33. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(Suppl 1):64S-94S.